MIEN1 (migration and invasion enhancer 1) is a membrane-anchored protein that functions as a critical regulator of cell migration and invasion in cancer progression. At the molecular level, MIEN1 undergoes post-translational prenylation and methylation modifications that anchor it to the plasma membrane 1, enabling interaction with key signaling partners including Syk kinase and Annexin A2 12. MIEN1 drives cell motility by promoting actin polymerization and stabilizing F-actin filaments while reducing cofilin phosphorylation 1, and induces filopodia formation through phosphorylation-dependent ITAM activation 2. Clinically, MIEN1 is significantly overexpressed in multiple cancer types including breast, prostate, and gastric cancers, correlating with poor survival outcomes and metastatic potential 345. In prostate cancer, MIEN1 functions as an NF-κB downstream oncogene promoting proliferation, invasion, and tumorigenesis through Akt/NDRG1/IL-6 signaling 4. In gastric cancer, MIEN1 activation of IL-6/JAK2/STAT3 pathway drives malignant behaviors 5. In lung cancer, HRD1-mediated inhibition of autophagy prevents MIEN1 degradation, promoting metastasis 6. Additionally, MIEN1 regulates tumor-associated neutrophil recruitment via CTCF-mediated expression, contributing to immunosuppression in colorectal cancer 7. These findings establish MIEN1 as an emerging therapeutic target across multiple cancer types.